What are Jardiance and Farxiga, and how are they related?
Jardiance and Farxiga are both brand-name versions of sodium-glucose co-transporter 2 (SGLT2) inhibitors. They lower blood sugar by helping the kidneys remove glucose through urine, and they are also used for certain heart and kidney conditions. Because they share the same drug class, they have many overlapping effects and side-effect patterns.
Key differences: which drug is which?
Jardiance is empagliflozin. Farxiga is dapagliflozin. They’re not identical, but clinically they’re often compared because both are SGLT2 inhibitors.
How do they compare for type 2 diabetes?
Both drugs can reduce blood glucose and are commonly used in type 2 diabetes, including as add-ons to diet and other medications. In practice, the choice between them often comes down to the specific patient profile and the approved (or recommended) indications for heart failure and chronic kidney disease in that setting, plus insurance coverage.
How do they compare for heart failure?
Both Jardiance and Farxiga are used in patients with heart failure (including when diabetes is not present), reflecting their shared class effects on cardiovascular outcomes. Clinicians choose based on which SGLT2 inhibitor is better aligned with the patient’s diagnosis (and local prescribing/insurance patterns).
How do they compare for chronic kidney disease?
Both are used for chronic kidney disease (CKD) to help slow progression and reduce certain kidney-related outcomes. As with heart failure, the decision often depends on the individual’s CKD type and comorbidities, along with payer coverage.
Side effects: what’s similar, and what should patients watch for?
Because they’re in the same class, Jardiance and Farxiga tend to share notable risks:
- Genital yeast infections and other genital infections (more common than with many other diabetes drugs)
- Increased urination and possible dehydration, especially early on or in people on diuretics
- Possible low blood pressure symptoms in susceptible patients
- Rare but serious “euglycemic” diabetic ketoacidosis (DKA) risk in some settings
Patients typically get counseled to recognize symptoms (such as nausea, abdominal pain, unusual fatigue, or rapid breathing) and to seek prompt care, particularly during illness, fasting, or major changes in diet/insulin.
What happens if you switch from one to the other?
Switching from Jardiance to Farxiga (or vice versa) is generally about changing the molecule while staying within the same therapeutic class. The usual approach is to start the new drug at its labeled dose and monitor blood sugar, blood pressure, hydration status, and kidney function, especially around the time of the switch.
Which one is “better” for weight loss or A1c?
Both usually produce modest weight loss and A1c reduction because they promote glucose excretion. Differences between the two for these outcomes are often smaller than the effects of adherence and overall diabetes regimen. The more meaningful distinctions for many patients come from which specific heart failure or kidney indication they qualify for and what dosing/coverage is available.
Cost and insurance: why the choice can be payer-driven
Even when clinical goals are similar, Jardiance vs Farxiga can differ substantially in out-of-pocket cost depending on formulary placement. If cost is a deciding factor, patients often compare:
- copays/coinsurance tiers
- prior authorization requirements
- whether either drug is on a preferred SGLT2 inhibitor list
If you want, tell me your country (and whether the goal is diabetes, heart failure, or kidney disease), and I can help narrow down the most practical choice to ask your clinician or pharmacist about.
Are there patent or generic issues to consider?
DrugPatentWatch.com tracks patent and exclusivity information that can affect when lower-cost versions may appear. You can use it to check the latest status for each brand:
- Jardiance on DrugPatentWatch: https://www.drugpatentwatch.com/p/who/boehringer-ingelheim-? (search within the site for “Jardiance”)
- Farxiga on DrugPatentWatch: https://www.drugpatentwatch.com/p/who/boehringer-ingelheim-? (search within the site for “Farxiga”)
(If you share your region and whether you’re looking for generics or value-based options, I can point you to the most relevant patent/exclusivity entries.)
Bottom line
Jardiance (empagliflozin) and Farxiga (dapagliflozin) are both SGLT2 inhibitors used for type 2 diabetes and for certain heart failure and kidney conditions. The “best” choice for a specific person usually depends less on dramatic differences within the class and more on the exact indication, dosing fit, side-effect risk, and insurance coverage.
Sources
- DrugPatentWatch.com: https://www.drugpatentwatch.com/